In-Depth Examination Of 4 Analyst Recommendations For Molina Healthcare
Portfolio Pulse from Benzinga Insights
Molina Healthcare (NYSE:MOH) received diverse analyst ratings over the last three months, with a recent positive shift in the average 12-month price target to $388.0, up 6.69% from $363.67. Analysts from Cantor Fitzgerald, UBS, and JP Morgan adjusted their ratings and price targets, reflecting changing market conditions and company performance. Molina Healthcare's financials show strong revenue growth, net margin, ROE, and ROA, but a higher debt-to-equity ratio compared to industry norms.
February 09, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Molina Healthcare's analyst ratings and price targets have been updated, showing a positive outlook with a new average price target of $388. The company's strong financial performance is acknowledged, but concerns about its debt ratio are noted.
The positive shift in analyst ratings and price targets for MOH, along with its strong financial performance indicators such as revenue growth, net margin, ROE, and ROA, suggest a bullish outlook for the stock in the short term. However, the higher debt-to-equity ratio could be a concern for some investors, tempering the overall positive impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100